Inceptor Bio to Present at ASGCT in Baltimore

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced two poster presentations at the ASGCT in Baltimore (AACR ANNUAL MEETING 2024) Poster Presentation #819: Presenter: Warren Anderson, Ph.D. Title: OUTLASTTM CAR-T Cells Exhibit Superior Effector Function Against Solid Tumors Date: May 8th, 2024 Time: 5:30pm EST Poster Presentation […]

Inceptor Bio to Present at AACR in San Diego

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the poster presentation at AACR in San Diego (AACR Annual Meeting 2024 in San Diego) Presenter: Kilsoo Jeon, Ph.D. Title: Novel costimulatory domain improves CAR-Monocyte activity against tumors Date: April 9th, 2024 Time: 1:30PM and 5:00PM PT About Inceptor […]

Inceptor Bio to Present at the BioCentury Inc. East-West Summit in Boston

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the presentation at the BioCentury-BayHelix East-West Summit 2023 Date: October 4, 2023 Time: 9:00 am EST About Inceptor Bio Founded in 2020, Inceptor Bio is a biotechnology company strategically advancing a pipeline of diversified cell therapies in oncology. Inceptor […]

Inceptor Bio to Present at CAR-TCR Summit in Boston

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the presentation at the CAR-TCR Summit in Boston (8th CAR-TCR Summit | Boston, MA (car-tcr-summit.com) Presenter: Sumiti Jain, PhD, VP of R&D Title: Overcoming Resistance & the Tumor Microenvironment with CAR-Macrophage Therapies Date: August 29th Time: 11am EST About […]

Inceptor Bio Appoints Matthias Schroff, PhD, as Chief Executive Officer

Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, announced the appointment of Dr. Matthias Schroff as CEO effective today. Dr. Schroff will also join the Board of Directors. Dr. Schroff succeeds Mr. Shailesh Maingi, who will remain as Executive Chairman. Dr. Schroff has extensive biopharmaceutical leadership experience with a track record […]

Ori Biotech and Inceptor Bio Partner to Accelerate Solid tumor Cell Therapy Access

Inceptor joins Ori’s LightSpeed Early Access Program (LEAP) to future proof manufacturing capabilities, ahead of its first clinical trials in 2024 Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technologies, and Inceptor Bio, a next-gen cell therapy biotechnology company, have announced a new partnership to utilize Ori Biotech’s manufacturing platform technology and […]

Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors

Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of next-generation CAR-T cell therapies for the treatment of solid tumors. Under the agreement, Inceptor will utilize Avectas’ SOLUPORE® technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell […]

Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel IPSC Platform

Morrisville, NC – June 30, 2022 – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced a collaboration with University of Minnesota. The aim of this collaboration is to build a novel induced pluripotent stem cells (iPSC) platform that will accelerate Inceptor Bio’s best-in-class next-generation cell therapies platforms. Under the terms of the […]

Inceptor Bio Announces $37 Million Series A Financing

Morrisville, NC – May 19, 2022 – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, today announced the closing of a $37 million Series A financing led by Kineticos Ventures. Proceeds from the Series A financing will be used to advance Inceptor Bio’s CAR-T lead program to a Phase I clinical trial […]